|
PL2694484T3
(pl)
|
2011-04-08 |
2019-02-28 |
Janssen Sciences Ireland Uc |
Pochodne pirymidyny do leczenia zakażeń wirusowych
|
|
PL2776439T3
(pl)
|
2011-11-09 |
2018-12-31 |
Janssen Sciences Ireland Uc |
Pochodne puryny do leczenia zakażeń wirusowych
|
|
ES2716811T3
(es)
*
|
2012-02-08 |
2019-06-17 |
Janssen Sciences Ireland Unlimited Co |
Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas
|
|
EP2872515B1
(en)
|
2012-07-13 |
2016-06-08 |
Janssen Sciences Ireland UC |
Macrocyclic purines for the treatment of viral infections
|
|
AU2013328732B2
(en)
|
2012-10-10 |
2017-08-31 |
Janssen Sciences Ireland Uc |
Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
|
|
MY171115A
(en)
|
2012-11-16 |
2019-09-26 |
Janssen Sciences Ireland Uc |
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
|
|
EA035174B1
(ru)
|
2013-02-21 |
2020-05-12 |
Янссен Сайенсиз Айрлэнд Юси |
Производные 2-аминопиримидина в качестве модуляторов толл-подобных рецепторов tlr7 и/или tlr8
|
|
PT2978429T
(pt)
|
2013-03-29 |
2017-05-24 |
Janssen Sciences Ireland Uc |
Deaza-purinonas macrocíclicas para o tratamento de infeções virais
|
|
UA117586C2
(uk)
|
2013-05-24 |
2018-08-27 |
ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі |
Похідні піридину для лікування вірусних інфекцій та інших захворювань
|
|
EA034893B1
(ru)
|
2013-06-27 |
2020-04-02 |
Янссен Сайенсиз Айрлэнд Юси |
Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
|
|
DK3404031T3
(da)
|
2013-07-30 |
2020-12-14 |
Janssen Sciences Ireland Unlimited Co |
Thieno[3,2-d]pyrimidinderivater til behandling af virusinfektioner
|
|
HUE038059T2
(hu)
|
2015-03-04 |
2018-10-29 |
Gilead Sciences Inc |
Toll-like receptor moduláló 4,6-diamino-pirido[3,2-D]pirimidin vegyületek
|
|
JP2018525412A
(ja)
|
2015-08-26 |
2018-09-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
重水素化トール様受容体調節因子
|
|
MA42818A
(fr)
|
2015-09-15 |
2018-07-25 |
Gilead Sciences Inc |
Modulateurs de récepteurs de type toll pour le traitement du vih
|
|
CN114848812B
(zh)
|
2015-12-15 |
2025-01-10 |
吉利德科学公司 |
人免疫缺陷病毒中和抗体
|
|
KR102202984B1
(ko)
|
2016-05-27 |
2021-01-13 |
길리애드 사이언시즈, 인코포레이티드 |
Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
AU2017289418B2
(en)
*
|
2016-07-01 |
2021-06-03 |
Janssen Sciences Ireland Unlimited Company |
Dihydropyranopyrimidines for the treatment of viral infections
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
ES2826748T3
(es)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
|
|
US10370342B2
(en)
*
|
2016-09-02 |
2019-08-06 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
WO2018047081A1
(en)
*
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Compounds and compositions as inhibitors of endosomal toll-like receptors
|
|
WO2018060317A1
(en)
|
2016-09-29 |
2018-04-05 |
Janssen Sciences Ireland Uc |
Pyrimidine prodrugs for the treatment of viral infections and further diseases
|
|
WO2018071849A2
(en)
|
2016-10-14 |
2018-04-19 |
Precision Biosciences, Inc. |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
|
TWI714820B
(zh)
|
2017-01-31 |
2021-01-01 |
美商基利科學股份有限公司 |
替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
AR112413A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas sólidas de un inhibidor de la cápside del vih
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
EP3672970A1
(en)
|
2017-08-22 |
2020-07-01 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
TW201915000A
(zh)
*
|
2017-09-22 |
2019-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合雜芳基衍生物、其製備方法及其在醫藥上的應用
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
JP2021506827A
(ja)
|
2017-12-15 |
2021-02-22 |
シルバーバック セラピューティックス インコーポレイテッド |
肝炎の治療用の抗体コンストラクト−薬物コンジュゲート
|
|
CA3084582A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111566120B
(zh)
|
2017-12-20 |
2023-09-29 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
|
|
WO2019160882A1
(en)
|
2018-02-13 |
2019-08-22 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
WO2019161017A1
(en)
|
2018-02-15 |
2019-08-22 |
Gilead Sciences, Inc. |
Pyridine derivatives and their use for treating hiv infection
|
|
CA3175384A1
(en)
|
2018-02-16 |
2019-08-22 |
Gilead Sciences, Inc. |
Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
|
|
WO2019165374A1
(en)
|
2018-02-26 |
2019-08-29 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds as hbv replication inhibitors
|
|
TWI772370B
(zh)
*
|
2018-02-26 |
2022-08-01 |
瑞士商諾華公司 |
作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物
|
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
CN112041311B
(zh)
|
2018-04-19 |
2023-10-03 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
TWI826446B
(zh)
|
2018-05-18 |
2023-12-21 |
瑞士商諾華公司 |
Tlr7/tlr8抑制劑之晶型
|
|
SG11202012043RA
(en)
|
2018-07-03 |
2021-01-28 |
Gilead Sciences Inc |
Antibodies that target hiv gp120 and methods of use
|
|
US11098027B2
(en)
|
2018-07-06 |
2021-08-24 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
AU2019297428C1
(en)
|
2018-07-06 |
2023-03-23 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
KR20230159715A
(ko)
|
2018-07-13 |
2023-11-21 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
TWI814350B
(zh)
|
2018-07-16 |
2023-09-01 |
美商基利科學股份有限公司 |
用於治療hiv之蛋白殼抑制劑
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
MX2021002764A
(es)
|
2018-09-12 |
2021-05-12 |
Silverback Therapeutics Inc |
Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
|
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
EP3870566A1
(en)
|
2018-10-24 |
2021-09-01 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
PE20211655A1
(es)
|
2018-10-31 |
2021-08-24 |
Gilead Sciences Inc |
Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
|
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
WO2020162705A1
(ko)
|
2019-02-08 |
2020-08-13 |
성균관대학교산학협력단 |
톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
|
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
KR102707808B1
(ko)
|
2019-03-07 |
2024-09-19 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
|
KR102808642B1
(ko)
|
2019-03-07 |
2025-05-14 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
HUE059677T2
(hu)
|
2019-03-22 |
2022-12-28 |
Gilead Sciences Inc |
Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202231277A
(zh)
|
2019-05-21 |
2022-08-16 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
US20220305115A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
US20220249685A1
(en)
|
2019-06-19 |
2022-08-11 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
|
AU2020301161B2
(en)
|
2019-06-25 |
2023-10-26 |
Gilead Sciences, Inc. |
FLT3L-Fc fusion proteins and methods of use
|
|
TWI879779B
(zh)
|
2019-06-28 |
2025-04-11 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
|
CA3145791A1
(en)
|
2019-07-16 |
2021-01-21 |
Gilead Sciences, Inc. |
Hiv vaccines and methods of making and using
|
|
US20220257619A1
(en)
|
2019-07-18 |
2022-08-18 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
KR20250040096A
(ko)
|
2019-09-30 |
2025-03-21 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 백신 및 hbv를 치료하는 방법
|
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
WO2021076908A1
(en)
|
2019-10-18 |
2021-04-22 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
WO2021108544A1
(en)
|
2019-11-26 |
2021-06-03 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of hiv
|
|
ES3022990T3
(en)
|
2019-12-06 |
2025-05-29 |
Prec Biosciences Inc |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
ES3001984T3
(en)
|
2019-12-24 |
2025-03-06 |
Carna Biosciences Inc |
Diacylglycerol kinase modulating compounds
|
|
BR112022014623A2
(pt)
|
2020-02-14 |
2022-09-13 |
Jounce Therapeutics Inc |
Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
|
|
WO2021168274A1
(en)
|
2020-02-21 |
2021-08-26 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
CN115666637A
(zh)
|
2020-03-02 |
2023-01-31 |
蛋白科技先锋 |
基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
|
|
AU2021237718B2
(en)
|
2020-03-20 |
2023-09-21 |
Gilead Sciences, Inc. |
Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
CA3181922A1
(en)
|
2020-05-01 |
2021-11-04 |
Gilead Sciences, Inc. |
Cd73 inhibiting 2,4-dioxopyrimidine compounds
|
|
JP7741100B2
(ja)
|
2020-05-04 |
2025-09-17 |
アムジェン インコーポレイテッド |
ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
|
|
TW202208355A
(zh)
|
2020-05-04 |
2022-03-01 |
美商安進公司 |
作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
|
|
WO2021236944A1
(en)
|
2020-05-21 |
2021-11-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
TWI858267B
(zh)
|
2020-06-25 |
2024-10-11 |
美商基利科學股份有限公司 |
用於治療hiv之蛋白殼抑制劑
|
|
CN116209678A
(zh)
|
2020-07-01 |
2023-06-02 |
安尔士制药公司 |
抗asgr1抗体缀合物及其用途
|
|
CN116322751A
(zh)
|
2020-08-04 |
2023-06-23 |
蛋白科技先锋 |
包含能够动力学控制的佐剂的mRNA疫苗
|
|
JP2023536954A
(ja)
|
2020-08-04 |
2023-08-30 |
プロジェニア インコーポレイテッド |
活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途
|
|
WO2022031011A1
(ko)
|
2020-08-04 |
2022-02-10 |
성균관대학교산학협력단 |
동력학적으로 작용하는 아주번트 앙상블
|
|
CN116194144A
(zh)
|
2020-08-07 |
2023-05-30 |
吉利德科学公司 |
膦酰胺核苷酸类似物的前药及其药物用途
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
US20220144923A1
(en)
|
2020-11-11 |
2022-05-12 |
Gilead Sciences, Inc. |
METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
|
|
JP7717832B2
(ja)
|
2021-04-10 |
2025-08-04 |
ジェンマブ エー／エス |
Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
US20250066490A1
(en)
|
2021-04-23 |
2025-02-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
KR20240006683A
(ko)
|
2021-05-13 |
2024-01-15 |
길리애드 사이언시즈, 인코포레이티드 |
TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물
|
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
|
JP7654118B2
(ja)
|
2021-06-23 |
2025-03-31 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022297367B2
(en)
|
2021-06-23 |
2025-04-10 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
EP4423078A1
(en)
|
2021-10-28 |
2024-09-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
TW202342447A
(zh)
|
2021-12-03 |
2023-11-01 |
美商基利科學股份有限公司 |
用於ｈｉｖ病毒感染之治療性化合物
|
|
TW202412779A
(zh)
|
2021-12-03 |
2024-04-01 |
美商基利科學股份有限公司 |
用於hiv病毒感染之治療性化合物
|
|
JP7765637B2
(ja)
|
2021-12-03 |
2025-11-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖウイルス感染症のための治療化合物
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
CN118382625A
(zh)
*
|
2021-12-08 |
2024-07-23 |
上海维申医药有限公司 |
作为TLR7/8激动剂的吡啶[4,3-d]嘧啶类化合物
|
|
AU2022417491A1
(en)
|
2021-12-22 |
2024-05-23 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
JP2024546851A
(ja)
|
2021-12-22 |
2024-12-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
US12358887B2
(en)
|
2022-03-17 |
2025-07-15 |
Gilead Sciences, Inc. |
IKAROS Zinc Finger Family degraders and uses thereof
|
|
KR20240165995A
(ko)
|
2022-03-24 |
2024-11-25 |
길리애드 사이언시즈, 인코포레이티드 |
Trop-2 발현 암의 치료를 위한 병용요법
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
TW202446773A
(zh)
|
2022-04-06 |
2024-12-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
PE20250157A1
(es)
|
2022-04-21 |
2025-01-22 |
Gilead Sciences Inc |
Compuestos de modulacion de kras g12d
|
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US20240034724A1
(en)
|
2022-07-01 |
2024-02-01 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
|
AU2023307100A1
(en)
|
2022-07-12 |
2025-01-02 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
CN119768183A
(zh)
|
2022-08-26 |
2025-04-04 |
吉利德科学公司 |
用于广泛中和抗体的给药和安排方案
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4598934A1
(en)
|
2022-10-04 |
2025-08-13 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN120882725A
(zh)
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
US20240390349A1
(en)
|
2023-04-19 |
2024-11-28 |
Gilead Sciences, Inc. |
Dosing regimen of capsid inhibitor
|
|
AU2024259556A1
(en)
|
2023-04-21 |
2025-10-23 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024281548A1
(en)
|
2023-05-31 |
2025-11-13 |
Gilead Sciences, Inc. |
Solid forms of compounds useful in the treatment of hiv
|
|
US20250042926A1
(en)
|
2023-05-31 |
2025-02-06 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025029247A1
(en)
|
2023-07-28 |
2025-02-06 |
Gilead Sciences, Inc. |
Weekly regimen of lenacapavir for the treatment and prevention of hiv
|
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250115680A1
(en)
|
2023-09-26 |
2025-04-10 |
Profoundbio Us Co. |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
TW202515549A
(zh)
|
2023-10-11 |
2025-04-16 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
TW202530227A
(zh)
|
2023-10-11 |
2025-08-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
US20250127801A1
(en)
|
2023-10-11 |
2025-04-24 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137245A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
US20250296992A1
(en)
|
2024-01-10 |
2025-09-25 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
US20250296932A1
(en)
|
2024-03-01 |
2025-09-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
US20250333424A1
(en)
|
2024-03-01 |
2025-10-30 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
US20250289822A1
(en)
|
2024-03-01 |
2025-09-18 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|